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Summary
Background: Limited data exist regarding tenofovir disoproxil fumarate (TDF) safety 
and effectiveness in chronic hepatitis B virus–infected (CHB) patients with renal im-
pairment (RI).
Aims: To compare real-world data on renal safety and effectiveness of TDF vs ente-
cavir (ETV) in CHB patients with moderate-to-severe RI.
Methods: Retrospective, non-interventional, cohort study analysing medical records 
for TDF/ETV-treated CHB patients (54 European centres). Included patients experi-
enced moderate-to-severe RI (creatinine clearance 20-60 mL/min [Cockcroft-Gault]) 
either before TDF/ETV initiation (‘before’ subgroup [baseline = treatment initiation]) 
or after TDF/ETV initiation (‘after’ subgroup [baseline = first RI occurrence]). The 
primary objective was TDF safety, particularly renal-related adverse events of special 
interest (AESI). TDF and ETV safety and effectiveness were compared and multivari-
ate analyses were performed using inverse probability treatment weighting.
Results: ‘Before’ subgroup included 107 TDF- and 91 ETV-treated patients; ‘after’ sub-
group included 212 TDF- and 77 ETV-treated patients. Mean baseline creatinine clear-
ance was higher for TDF- vs ETV-treated patients (both subgroups). Median follow-up 
was 3.1 years (both treatments). AESI were more frequent with TDF vs ETV (‘before’: 
18.7% vs 8.8%; ‘after’: 9.9% vs 3.9%); however, differences were not significant by 
multivariate analysis. Only TDF-treated patients experienced renal tubular dysfunction 
(6.5% ‘before’; 1.9% ‘after’) as well as renal adverse events leading to treatment discon-
tinuation (8.4% ‘before’; 7.1% ‘after’). Effectiveness was similar between treatments.
This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
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1  | INTRODUC TION
Hepatitis B virus (HBV) affects around 257 million people worldwide, 
with chronic HBV infection (CHB) leading to a significant number 
of deaths due to cirrhosis and hepatocellular carcinoma.1 Tenofovir 
disoproxil fumarate (TDF) is a nucleotide analogue prodrug of teno-
fovir diphosphate, which inhibits HBV polymerase and exerts potent 
anti-HBV activity.2,3 The efficacy and safety of TDF were main-
tained over 7 years of treatment in pivotal Phase III trials, with no 
resistance detected.4,5 Furthermore, TDF treatment over 5 years 
was associated with regression of liver fibrosis and cirrhosis.6 TDF 
is authorised for treatment of CHB in adult and paediatric patients 
(≥2 years of age), including those with pre-existing renal impairment 
(with dose adjustment),7,8 and is a preferred first-line treatment for 
adult CHB patients.9-11
Despite its favourable safety profile, some tenofovir-exposed 
patients experience renal toxicity,5,12 since tenofovir is primarily 
excreted via glomerular filtration and active tubular transport.7,13 
Long-term follow-up of CHB patients enrolled in TDF registra-
tional studies with adequate renal function at baseline showed a 
low incidence of renal events.5,6 However, several real-world ob-
servational studies reported an increased risk of nephrotoxicity 
with TDF, manifesting as proximal tubular dysfunction with/with-
out decreased glomerular filtration rates.12,14,15 A recent review 
highlighted conflicting evidence regarding nephrotoxicity,12 with 
several studies subsequently reporting a lack of significant renal 
safety findings.16-21
CHB patients, particularly those with advanced age or comor-
bidities (eg hypertension/diabetes mellitus), have a relatively high 
prevalence of kidney disease,22 even in the absence of anti-viral 
treatment.23 Despite this, limited data exist regarding the safety and 
effectiveness of TDF in CHB patients with renal insufficiency: pa-
tients with pre-existing renal impairment were excluded from most 
Phase III trials, which required creatinine clearance ≥70 mL/min for 
inclusion.4 However, a Phase III study evaluating TDF in patients 
with lamivudine resistance enrolled CHB patients with creatinine 
clearance ≥50 mL/min and included 74 patients with mild renal im-
pairment.24 Six of the nine patients who experienced a reduction 
in creatinine clearance below 50 mL/min were managed by dose 
modification, and there were no severe renal adverse events (AEs).24 
Furthermore, a non-interventional, prospective cohort study found 
a favourable safety profile among a small number of patients with 
pre-existing renal impairment.16 However, retrospective/retrospec-
tive-prospective studies have linked pre-existing renal impairment 
to further decline in renal function with TDF.25-27 The limited num-
ber of HBV-infected patients in these studies means that they may 
not be generalisable for a broader renally impaired CHB population. 
TDF treatment has also been associated with Fanconi syndrome in 
rare instances.12
Current TDF labelling reflects the risk of renal toxicity, recom-
mending that creatinine clearance is evaluated prior to treatment 
and renal function is monitored regularly (and more frequently in 
patients with renal impairment risk factors).7 The requirement for 
periodic renal monitoring for all TDF-treated patients is reflected in 
current guidelines.9,10 EU labelling indicates that TDF should only be 
used in adult patients with pre-existing renal impairment ‘if the po-
tential benefits of treatment are considered to outweigh the poten-
tial risks’.7 Additionally, dose adjustment or extended-interval dosing 
is recommended for patients with creatinine clearance <50 mL/min.7
Entecavir (ETV), a guanosine nucleoside analogue inhibitor of 
HBV polymerase,28 is a first-line treatment option for CHB.9,10 ETV is 
effective and well tolerated.12,29,30 As it is eliminated renally,31 dose 
adjustment is recommended in patients with renal impairment (cre-
atinine clearance <50 mL/min).28 Despite renal safety findings being 
similar for TDF and ETV in several retrospective studies,29,30,32,33 
ETV has been associated with a lower risk of proximal tubular tox-
icity than TDF, independent of pre-existing renal impairment.34,35 
A retrospective study evaluated ETV in HBV-infected patients, in-
cluding 40 with renal dysfunction (estimated glomerular filtration 
rate ≤59 mL/min or receiving haemodialysis).36 While outcomes 
were similar between groups, estimated glomerular filtration rates 
declined over 5 years in patients without renal dysfunction at base-
line (who had Grade 1-2 chronic kidney disease), but this was not 
observed in those with baseline renal dysfunction.36 Nonetheless, 
guidelines recommend renal monitoring for all patients at risk of 
renal disease, regardless of the nucleoside analogue received.10
This retrospective, observational study was undertaken at the 
request of the European Medicines Agency to provide real-world 
data on the renal safety and effectiveness of TDF and ETV in CHB 
patients with moderate or severe renal impairment.37 We report 
findings for the subgroups of patients with pre-existing renal impair-
ment before treatment initiation, or renal impairment that was first 
experienced after treatment initiation.
2  | MATERIAL S AND METHODS
2.1 | Study design
This was a multicentre, retrospective, non-interventional, cohort 
study that included patients with chronic HBV infection undergoing 
treatment between 23 April 2008 (date of European marketing au-
thorisation for the HBV indication for TDF tablets) and 31 December 
2015. De-identified data were retrospectively collected from routine 
Conclusions: Overall safety was similar for TDF vs ETV (both subgroups). Given that 
renal tubular dysfunction occurred with TDF and not with ETV, renal safety concerns 
may be greater with TDF in CHB patients with RI.
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medical records at 54 centres in five European countries (France, 
Germany, Italy, Spain and the UK). Electronic case report forms em-
ploying unique patient identifiers and automatic checks for data com-
pleteness and inconsistencies were utilised. Patients had to fulfil two 
criteria to be included in the study and for data collection to com-
mence, irrespective of which came first: (a) treatment with TDF or 
ETV and (b) moderate-to-severe renal impairment, defined by a cre-
atinine clearance of 20-60 mL/min inclusive (based on the Cockcroft-
Gault formula; hereafter referred to as renal impairment). Baseline 
was either: the date of treatment initiation (for the subgroup with 
renal impairment before treatment initiation); or the date of first oc-
currence of renal impairment if treatment had already been initiated 
(for the subgroup experiencing first renal impairment after treatment 
initiation). Data were collected during the post-baseline treatment 
period and for 12 weeks following drug discontinuation and/or re-
placement with another HBV medication, or 31 December 2015, 
whichever occurred first. The post-treatment observation period was 
extended to 6 months or 31 December 2015 (whichever occurred 
first), when discontinuation was due to decreasing renal function.
The study was conducted in accordance with the International 
Conference on Harmonisation E2E guidelines, the Guidelines 
for Good Pharmacoepidemiology Practices and EU Good 
Pharmacovigilance Practices. Participating centres adhered to any 
additional local ethical approval requirements. Since patient infor-
mation was de-identified, informed consent was not obtained un-
less required by local ethics committees or by country National Data 
Protection Laws for participating centres. The study is registered 
with the EU PAS Register: EUPAS12897.
2.2 | Study participants
Participants were adults (≥18 years) with CHB who had experienced 
renal impairment as previously described. Patients had received 
monotherapy with either TDF (tablets [once-daily or extended-in-
terval dosing for renal impairment] and/or oral granules [once-daily 
and reduced dose for renal impairment]), or ETV (tablets [once-daily] 
and/or oral solution). Patients were excluded if they had human im-
munodeficiency virus (HIV), hepatitis C virus or hepatitis D virus 
coinfection or received anti-HBV combination treatment during 
the renal impairment episode. If a patient received both drugs but 
without temporal overlap, the patient was allocated to the group 
corresponding to the drug received at the first occurrence of renal 
impairment. Concomitant nephrotoxic medications were recorded 
as an indicator variable (‘yes/no’).
2.3 | Study objectives and variables
The primary objective was to evaluate the safety of TDF in CHB 
patients with renal impairment—focusing on AEs of special inter-
est, defined as: ‘renal tubular dysfunction AEs’, ‘renal AEs leading 
to treatment discontinuation’, ‘renal AEs leading to initiation of 
haemodialysis (or other forms of renal support)’, ‘renal serious AEs 
(SAEs) including those leading to death’ and ‘decline in renal function’ 
(if reported as an AE by the investigator). ‘Renal tubular dysfunction 
AEs’ were defined by combining reports of renal tubulopathy, includ-
ing proximal renal tubulopathy, Fanconi syndrome and renal tubular 
necrosis. Renal AEs included AEs coded to the renal and urinary dis-
order System Organ Class as well as AEs reflecting renal concepts 
that were coded to the investigations or metabolism and nutrition 
disorders System Organ Classes per the Medical Dictionary for 
Regulatory Affairs version 20.0.
The secondary objective was to describe the effectiveness of 
TDF in this patient population; the tertiary objective was to com-
pare the safety and effectiveness of TDF and ETV. Response to 
therapy was defined as achievement and/or maintenance of HBV 
DNA <69 IU/mL (400 copies/mL). Table S1 details baseline, safety, 
laboratory and effectiveness variables. Subgroup analyses (see 
Supplementary Methods) were conducted to further evaluate AEs of 
special interest and effectiveness. Time-to-event analyses were car-
ried out to compare time to renal impairment and time to further ag-
gravation of renal impairment (see Supplementary Methods). Results 
are presented herein for the pre-defined subgroups of patients with 
pre-existing renal impairment and patients with renal impairment 
after treatment initiation.
2.4 | Statistical analyses
The study size was based on the primary objective only and was de-
termined based on a 3.4% cumulative incidence of renal AEs lead-
ing to dose reduction, treatment interruption or discontinuation 
in patients receiving TDF during the open-label period of Phase III 
studies.38,39 Using this value as the expected incidence rate and ac-
counting for 80% statistical power, a one proportion test determined 
that a sample size of 300 patients in the TDF group would detect an 
effect size of 3.1%. Since the study size was based on the primary 
objective, no estimates were made for the size of the ETV group.
Data were first summarised descriptively. Baseline characteris-
tics were compared between overall TDF/ETV groups using a back-
ward selection logistic regression model, with the ETV group as the 
referent. Differences between groups for some variables, including 
relevant comorbidities (ie hyperlipidaemia, hypertension or diabe-
tes), required implementation of an inverse probability treatment 
weighted approach to compare safety and effectiveness between 
drugs, maximising homogeneity between groups and reducing the 
impact of treatment-selection bias. All statistical tests were two-
tailed considering a 5% significance level. For the primary objective, 
the incidence rate of TDF-treated patients experiencing AEs of spe-
cial interest at each 48-week (±12 week) visit window (from baseline) 
was calculated. Person-time for denominators of rates was calcu-
lated as the date of the first instance of the AE of special interest 
minus the date of treatment initiation +1 day, or date of last observa-
tion minus date of treatment initiation +1 day, whichever came first. 
To compare the incidence of AEs of special interest between groups, 
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incidence rate ratios were calculated with ETV as the reference. All 
statistical analyses used SAS software (SAS Institute). Statistical 
analyses are further detailed in Supplementary Methods.
3  | RESULTS
3.1 | Patient disposition
Of 515 patients with renal impairment examined for eligibility, 487 
were included in the analysis (319 TDF, 168 ETV; Figure 1). Most 
of the 28 patients who were excluded had important protocol de-
viations including the first episode of renal impairment occurring 
under a previous therapy or the first available confirmatory cre-
atinine clearance laboratory values not matching the definition of 
renal impairment used in the study. The median (interquartile range 
[minimum-maximum] duration of follow-up was 3.1 (1.3-4.8 [0-7.7]) 
and 3.1 (1.4-5.6 [0.1-7.7]) years in the TDF and ETV groups respec-
tively, with a total respective follow-up person-time of 1015.4 and 
594.0 years given differences in sample size between treatment 
groups. Of 198 patients with renal impairment before treatment 
initiation, 107 and 91 were TDF- and ETV-treated respectively 
(Figure 1). Overall, 289 patients experienced their first episode 
of renal impairment after treatment initiation (212 TDF, 77 ETV). 
Baseline patient disposition and disease characteristics are shown 
per renal impairment subgroup in Table 1 (Table S2 shows number of 
patients with missing data for each variable). Age (Figure 2) and sex 
(Table 1) distributions were similar between groups.
A lower proportion of TDF- vs ETV-treated patients had pre-ex-
isting renal impairment (33.5% vs 54.2%). At baseline, mean (95% 
confidence interval [CI]) creatinine clearance was 48.5 (46.3-50.7) 
and 43.9 (41.0-46.7) mL/min in the TDF and ETV groups respec-
tively in patients with pre-existing renal impairment (Table 1). For 
patients with renal impairment after treatment initiation, the mean 
(95% CI) creatinine clearance at first occurrence of renal impairment 
(baseline) was 53.8 (52.7-54.8) and 47.8 (45.2-50.5) mL/min in the 
TDF and ETV groups respectively (Table 1).
For both renal impairment subgroups, a greater proportion 
of TDF- vs ETV-treated patients were treatment-experienced 
(Figure 3). Most patients received TDF or ETV as a once-daily tab-
let at baseline and during the observation period (Figure 4). During 
the observation period, 51.4% and 27.5% of patients with pre-ex-
isting renal impairment and 45.3% and 18.2% of patients with renal 
impairment after treatment initiation received extended-interval 
dosing in TDF and ETV groups respectively. Few patients received 
reduced-dose treatment (with the oral granules) given once-daily.
3.2 | Safety in patients with pre-existing 
renal impairment
Among patients with pre-existing renal impairment, 28 (26.2%) TDF-
treated patients experienced 38 AEs, including 9 SAEs, while 12 
(13.2%) ETV-treated patients experienced 15 AEs, including 6 SAEs 
(Table 2). Treatment-related AEs were experienced by 21 (19.6%) and 
4 (4.4%) TDF- and ETV-treated patients respectively. TDF dosing was 
F I G U R E  1   Patient flow diagram. 
†Moderate-to-severe renal impairment: 
creatinine clearance 20-60 mL/min (per 
Cockcroft–Gault formula). ETV, entecavir; 
TDF, tenofovir disoproxil fumarate
515 patients with renal impairment† 
recruited and examined for eligibility
(345 TDF/170 ETV)
487 patients included for analysis 
(319 TDF/168 ETV)
198 patients included




in renal impairment after
treatment initiation subgroup 
(212 TDF/77 ETV)
28 patients excluded
Important protocol deviation (n = 23)
No information available for treatment
episode involving renal impairment (n = 2)
Loss to follow-up (n = 2)
Data inconsistencies (n = 1) 
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n (%) or median (interquartile range)c 
Renal impairment before treatment 
initiation Renal impairment after treatment initiation
TDF (N = 107) ETV (N = 91) TDF (N = 212) ETV (N = 77)
Sex Male 67 (62.6) 62 (68.1) 151 (71.2) 54 (70.1)
Female 40 (37.4) 29 (31.9) 61 (28.8) 23 (29.9)
Clinical evidence of cirrhosisd  No 56 (52.3) 64 (70.3) 124 (58.5) 55 (71.4)
Yes 31 (29.0) 18 (19.8) 86 (40.6) 18 (23.4)
Missing 20 (18.7) 9 (9.9) 2 (0.9) 4 (5.2)
Clinical evidence of decompensated liver 
disease
No 85 (79.4) 72 (79.1) 199 (93.9) 65 (84.4)
Yes 4 (3.7) 5 (5.5) 11 (5.2) 7 (9.1)
Missing 18 (16.8) 14 (15.4) 2 (0.9) 5 (6.5)
Previous HBV treatment before TDF or ETV 
initiation
No 39 (36.4) 47 (51.6) 65 (30.7) 52 (67.5)
Yes 68 (63.6) 44 (48.4) 147 (69.3) 25 (32.5)
Concomitant use of potentially nephrotoxic 
or NSAID drugs
No 91 (85.0) 73 (80.2) 175 (82.5) 67 (87.0)
Yes 16 (15.0) 18 (19.8) 37 (17.5) 10 (13.0)
Presence of hyperlipidaemia, hypertension 
or diabetese 
No 56 (52.3) 25 (27.5) 107 (50.5) 24 (31.2)
Yes 51 (47.7) 66 (72.5) 105 (49.5) 53 (68.8)
Hyperlipidaemia 8 (7.5) 20 (22.0) 22 (10.4) 16 (20.8)
Hypertension 47 (43.9) 54 (59.3) 92 (43.4) 48 (62.3)
Diabetes 18 (16.8) 26 (28.6) 28 (13.2) 14 (18.2)
Duration of CHB infection, y 107|91
212|77
9.1 (0.2-19.1) 4.6 (0.8-15.2) 11.5 (5.0-20.4) 4.6 (0.8-13.2)
Duration of previous HBV treatment, y 96|91
204|74
3.3 (0.0-9.7) 0.0 (0.0-6.1) 4.9 (0.0-10.7) 0.0 (0.0-1.0)
Serum albumin, g/L 45|35
151|46
45.0 (40.0-46.0) 42.0 (37.0-45.0) 44.7 (41.0-47.0) 40.9 (35.0-43.0)
Alanine aminotransferase, μkat/L 63|46
200|68
0.4 (0.2-0.6) 0.6 (0.4-1.0) 0.4 (0.4-0.6) 0.4 (0.2-0.6)
Aspartate aminotransferase, μkat/L 63|45
190|67
0.4 (0.4-0.6) 0.4 (0.4-1.0) 0.4 (0.4-0.6) 0.4 (0.4-0.6)
Serum bilirubin, μmol/L 61|45
151|65
10.3 (7.5-15.6) 10.4 (7.0-15.9) 10.0 (6.8-15.0) 10.6 (8.6-15.9)
BMI 102|83
187|72
23.4 (21.1-26.3) 24.6 (22.4-27.4) 25.1 (22.8-27.4) 26.2 (23.3-28.5)




48.5 (46.3-50.7) 43.9 (41.0-46.7) 53.8 (52.7-54.8) 47.8 (45.2-50.5)
Serum HBV DNA, log10 IU/mL 62|44
186|58
2.6 (1.6-7.7) 4.6 (2.2-15.6) 0.0 (0.0-2.9) 2.9 (1.4-4.2)
International normalised ratio 52|41
159|51
1.0 (1.0-1.1) 1.0 (1.0-1.1) 1.0 (1.0-1.1) 1.0 (1.0-1.2)
Platelet count, thousand/μL 67|50
198|72
187.0 (152.0-220.0) 185.0 (136.0-228.0) 181.0 (147.0-224.0) 185.5 (139.5-222.5)
Serum phosphate, mmol/L 42|25
153|38
0.8 (0.6-1.0) 1.1 (0.8-1.1) 1.0 (0.8-1.1) 1.1 (1.0-1.5)
Abbreviations: BMI, body mass index; CHB, chronic hepatitis B virus infection; CI, confidence interval; ETV, entecavir; HBeAg, hepatitis B e antigen; 
HBV, hepatitis B virus; NSAID, nonsteroidal anti-inflammatory drug; TDF, tenofovir disoproxil fumarate.
aFor categorical variables, category is shown. 
bFor continuous variables, the number of evaluable patients in each treatment group is indicated: the evaluable N for the renal impairment before 
treatment initiation subgroup is shown in the first row and the evaluable N for the renal impairment after treatment initiation subgroup is shown in 
the second row. Note that the number of participants with missing data are shown in Table S2 and age is presented in Figure 2. 
cn (%) and median (interquartile range) are shown for categorical and continuous variables respectively, unless otherwise stated. 
dEvidence indicated by the site investigator. 
ePatients could have multiple comorbidities. 
fCreatinine clearance was 20-60 mL/min for all patients. 
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altered following AEs in 18 patients (64.3% of the 28 patients who 
experienced AEs). Twenty (18.7%) TDF-treated patients experienced 
21 AEs of special interest, while 8 (8.8%) ETV-treated patients expe-
rienced 9 AEs of special interest (Table 3). For TDF-treated patients, 
the most frequent AE of special interest was renal AEs leading to 
treatment discontinuation, experienced by 8.4% of patients, while 
7.5%, 6.5% and 3.7% of patients experienced a decline in renal func-
tion (reported as an AE), renal tubular dysfunction AEs and renal SAEs 
respectively. Decline in renal function and renal SAEs were reported 
by 7.7% and 2.2% of ETV-treated patients. There were no incidences 
of renal tubular dysfunction AEs or renal AEs leading to treatment 
discontinuation in ETV-treated patients. Frequencies of AEs of spe-
cial interest were numerically higher in the TDF compared with the 
ETV group but, given the relatively small number of events, the inci-
dence rate ratio for AEs of special interest did not achieve statistical 
significance (2.05 [95% CI: 0.89-4.75]; P = 0.094). In addition, there 
was no statistical difference in incidence rate ratio between treat-
ments when evaluated by subgroups (Table S3). No renal SAEs lead-
ing to death (Table 3) or renal AEs leading to dialysis (or other forms of 
renal support) were reported for either treatment group. Mean cre-
atinine clearance remained relatively stable over time in TDF-treated 
patients, while it tended to increase slightly in ETV-treated patients 
(Figure S1). However, it should be noted that the creatinine clearance 
values are not directly comparable between treatment groups due 
to the differences at baseline. Interpretation is further challenged by 
the low number of evaluable patients at later time points. Modelling 
of time to development of renal impairment, controlling for baseline 
characteristics and prior adefovir treatment, was not statistically dif-
ferent between TDF and ETV, nor was modelling of further aggrava-
tion of renal impairment (see Supplementary Results).
3.3 | Safety in patients with renal impairment after 
treatment initiation
Of the patients with renal impairment occurring after treatment 
initiation, 38 (17.9%) TDF-treated patients experienced 51 AEs, in-
cluding 19 SAEs, while 7 (9.1%) ETV-treated patients experienced 9 
AEs, including 7 SAEs (Table 2). Treatment-related AEs were experi-
enced by 24 (11.3%) and 4 (5.2%) of TDF- and ETV-treated patients 
respectively. TDF dosing was altered following AEs in 20 patients 
(52.6% of the 38 patients who experienced AEs). Twenty-one (9.9%) 
TDF-treated patients experienced 27 AEs of special interest, while 
3 (3.9%) ETV-treated patients experienced 3 AEs of special interest 
F I G U R E  2   Age distribution of TDF- and ETV-treated patients. Patients with renal impairment before (A) and after (B) treatment initiation. 
Age was collected in 5-year groups. ETV, entecavir; TDF, tenofovir disoproxil fumarate
TDF (n = 212)
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(Table 3). For TDF-treated patients, the most frequent AE of special 
interest was renal AEs leading to treatment discontinuation, expe-
rienced by 7.1% of patients, while 4.2%, 2.4% and 1.9% of patients 
experienced a decline in renal function, renal SAEs, and renal tubu-
lar dysfunction AEs respectively. Decline in renal function and renal 
SAEs were experienced by 2.6% and 1.3% of ETV-treated patients; 
none experienced renal tubular dysfunction AEs or renal AEs leading 
to treatment discontinuation. Although numerically higher propor-
tions of TDF-treated patients experienced these AEs, the incidence 
rate ratio for AEs of special interest did not differ between treatment 
groups overall (2.30 [95% CI: 0.27-19.84]; P = 0.447) or in further 
subgroup analyses (Table S3). There were no renal SAEs leading to 
death (Table 3) or renal AEs leading to dialysis (or other forms of renal 
support) in either treatment group. In both treatment groups, mean 
creatinine clearance tended to slightly decrease over time (Figure S1), 
although these data should be interpreted with caution given the few 
observations at later time points, as noted previously. Modelling of 
time to further aggravation of renal impairment was not statistically 
different between TDF and ETV (see Supplementary Results).
3.4 | Effectiveness of TDF and ETV
In patients with pre-existing renal impairment and in those with 
renal impairment after treatment initiation, there were no differ-
ences between the TDF and ETV treatment groups in the likelihood 
of achieving HBV DNA levels <69 IU/mL (Table S4). The hazard ratio 
(95% CI) of TDF- vs ETV-treated patients for achieving and/or main-
taining viral suppression was 1.1 (0.61-1.8) in the subgroup of pa-
tients with pre-existing renal impairment and 0.99 (0.44-2.22) in the 
subgroup of patients with renal impairment after treatment initia-
tion. Findings were similar among further patient subgroups.
4  | DISCUSSION
This retrospective, non-interventional cohort study was undertaken 
to address the paucity of data regarding the safety and effective-
ness of TDF and ETV in CHB patients with moderate or severe renal 
impairment (creatinine clearance 20-60 mL/min): an issue despite 
the fact that these two first-line treatments have been approved for 
use for over 12 years.28,40-42 The study evaluated patients receiving 
TDF or ETV who had pre-existing renal impairment, as well as those 
who developed renal impairment after treatment with either of the 
agents was initiated. To our knowledge, this is the largest evaluation 
to date of TDF in CHB patients with this degree of renal impairment, 
providing insight into these two important patient populations.
In this study, the overall safety profile was similar between 
TDF and ETV for both renal impairment subgroups. A higher pro-
portion of AEs of special interest was observed in TDF- compared 
with ETV-treated patients for both subgroups. However, incidence 
rate ratios did not significantly differ between treatments following 
F I G U R E  3   Distribution of patients 
in each subgroup according to prior 
treatment and renal AE. Patients with 
renal impairment before (A) and after 
(B) treatment initiation. Annotated 
numbers show the number of patients 
in each subgroup. AE, adverse event; 
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implementation of an inverse probability treatment-weighted ap-
proach, which enables comparison of the treatment groups given 
the differences in baseline characteristics. The one exception to 
this was the significant difference in incidence rate ratio between 
TDF- and ETV-treated patients with pre-existing renal impairment 
for treatment-related AEs, which is in keeping with the well-under-
stood safety profile for TDF. However, renal tubular dysfunction AEs 
and renal AEs leading to drug discontinuation were only reported in 
TDF-treated patients. Not unexpectedly, there was also no observed 
difference in effectiveness (HBV DNA suppression) between TDF 
and ETV, regardless of renal impairment subgroup.
Chronic hepatitis B virus–infected patients with renal impair-
ment are predisposed to experience further decline in renal func-
tion once anti-HBV treatment is initiated.26,29,35,43 In this analysis, 
baseline creatinine clearance was lower in ETV- vs TDF-treated 
patients with pre-existing renal impairment, suggesting that clini-
cians might prefer to prescribe ETV for individuals with diminished 
renal function, per treatment guidelines.9,10 A greater proportion 
of patients with pre-existing renal impairment experienced AEs 
of special interest compared with those who experienced renal 
impairment after treatment initiation, emphasising the impor-
tance of this risk factor in treatment selection. The safety find-
ings in this real-world cohort study are consistent with the known 
safety profiles of TDF and ETV, and underscore the importance 
of regular renal function monitoring and dose adjustment, where 
appropriate, in clinical practice, as described in current product la-
belling and recommended in current international clinical practice 
guidelines.7,9,10,28
Our observation of renal tubular dysfunction AEs and renal AEs 
leading to treatment discontinuation in TDF-treated patients, but not 
in those who received ETV, is in keeping with the established renal 
safety concerns with TDF treatment. While TDF has an established 
role in the treatment of CHB patients, new options are becoming 
available that may offer an improved renal safety profile: tenofovir 
alafenamide (TAF) has received authorisation for the treatment of 
CHB in over 75 countries worldwide (data on file—Gilead Sciences, 
Inc), including the USA44 and members of the EU.45 In head-to-head 
trials in CHB patients with baseline creatinine clearance ≥50 mL/min, 
TAF demonstrated non-inferiority to TDF at Weeks 48 and 96 in terms 
of efficacy.46-48 Importantly, treatment with TAF was associated with 
lower rates of renal and bone abnormalities compared with TDF.46-48 
Switching from TDF to TAF was also associated with improvements in 
renal and bone parameters (with non-inferior efficacy), in a study eval-
uating this switch in 243 patients with CHB.49 Some markers of renal 
tubular function also improved in another study of 75 CHB patients 
(including 8 patients with creatinine clearance <60 mL/min), following 
a switch from TDF to TAF.50 In addition, renal function was improved 
in CHB patients with renal impairment 24 weeks after switching 
from TDF to TAF, including in those with end-stage renal disease on 
chronic haemodialysis.51 No dose adjustment is required for TAF in 
F I G U R E  4   Dosage forms and 
schedules at baseline and during the 
observation period. Patients with renal 
impairment before (A) and after (B) 
treatment initiation. Some patients 
switched between dosing forms during 
the observation period. ETV, entecavir; 
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CHB patients with creatinine clearance ≥15 mL/min (or <15 mL/min 
in patients receiving haemodialysis),52 thus TAF represents an import-
ant new treatment option for CHB patients with renal impairment. In 
accordance with this, TAF, along with ETV, is preferred over TDF in 
current treatment guidelines for certain at-risk CHB patients, includ-
ing those with renal impairment or bone disease.9,10 Studies evaluating 
TAF are ongoing and long-term data are awaited.
Regardless of renal impairment subgroup, there was no evidence 
for a difference in effectiveness between TDF and ETV, in agreement 
with the equivalent long-term efficacy of TDF and ETV described pre-
viously.53-55 However, data from patients with more than 48 weeks of 
continuous treatment were limited, and accurate retrospective assess-
ment of effectiveness can be challenging due to differences in HBV 
DNA monitoring frequency and assay cut-offs between study centres.
TA B L E  2   Incidence rate ratios of TDF- and ETV-treated patients experiencing an AE by renal impairment subgroup
Subgroup Treatment







Rate per 1000 person-
years (95% CI)b 








ETV 15 12 (13.2) 314.9 38.1 (19.7-66.6) Reference —
TDF 38 28 (26.2) 375.3 74.6 (49.6-107.8) 1.73 (0.87-3.41) 0.116
Treatment-
related AEs
ETV 4 (26.7) 4 (4.4) 327.1 12.2 (3.3-31.3) Reference —
TDF 27 (71.1) 21 (19.6) 385.4 54.5 (33.7-83.3) 4.76 (1.52-14.91) 0.007
AE leading to 
deathd,e 
ETV 4 (26.7) 3 (3.3) 337.2 8.9 (1.8-26.0) Reference —
TDF 5 (13.2) 3 (2.8) 417.5 7.2 (1.5-21.0) 1.08 (0.16-7.10) 0.936
Renal AEs ETV 11 (73.3) 10 (11.0) 312.5 32.0 (15.3-58.9) Reference —
TDF 24 (63.2) 22 (20.6) 380.7 57.8 (36.2-87.5) 1.50 (0.72-3.14) 0.277
SAEs ETV 6 (40.0) 5 (5.5) 331.6 15.1 (4.9-35.2) Reference —
TDF 9 (23.7) 7 (6.5) 409.2 17.1 (6.9-35.2) 1.15 (0.34-3.85) 0.820
Renal SAEs ETV 2 (13.3) 2 (2.2) 329.7 6.1 (0.7-21.9) Reference —
TDF 4 (10.5) 4 (3.7) 410.9 9.7 (2.7-24.9) 1.12 (0.23-5.52) 0.887




ETV 9 7 (9.1) 370.6 18.9 (7.6-38.9) Reference —
TDF 51 38 (17.9) 1000.1 38.0 (26.9-52.2) 2.03 (0.62-6.61) 0.239
Treatment-
related AEs
ETV 4 (44.4) 4 (5.2) 373.2 10.7 (2.9-27.4) Reference —
TDF 29 (56.9) 24 (11.3) 1005.7 23.9 (15.3-35.5) 1.91 (0.45-8.07) 0.381
AE leading to 
deathd,f 
ETV 6 (66.7) 4 (5.2) 376.7 10.6 (2.9-27.2) Reference —
TDF 12 (23.5) 8 (3.8) 1029.1 7.8 (3.4-15.3) 0.89 (0.17-4.59) 0.887
Renal AEs ETV 3 (33.3) 3 (3.9) 370.4 8.1 (1.7-23.7) Reference —
TDF 33 (64.7) 26 (12.3) 1009.3 25.8 (16.8-37.7) 3.49 (0.42-28.70) 0.245
SAEs ETV 7 (77.8) 5 (6.5) 374.0 13.4 (4.3-31.2) Reference —
TDF 19 (37.3) 13 (6.1) 1025.9 12.7 (6.7-21.7) 0.88 (0.20-3.81) 0.860
Renal SAEs ETV 1 (11.1) 1 (1.3) 373.9 2.7 (0.1-14.9) Reference —
TDF 9 (17.6) 5 (2.4) 1025.3 4.9 (1.6-11.4) 1.61 (0.03-81.81) 0.812
Abbreviations; AE, adverse event; CI, confidence interval; ETV, entecavir; SAE, serious adverse event; TDF, tenofovir disoproxil fumarate.
aMultiple AEs could occur in a single patient. 
bBased on time to first experienced AE. 
cIncidence rate ratio was calculated using multiple imputation and an inverse probability treatment weighted approach. 
dFor patients with multiple AEs leading to death, only one AE was counted. One TDF-treated patient with renal impairment before treatment 
initiation experienced three AEs leading to death and one TDF-treated patient with renal impairment after treatment initiation experienced two AEs 
leading to death. 
eThree TDF-treated patients died due to malignancy (n = 2) and haemorrhagic shock (n = 1). Three ETV-treated patients died due to chronic 
lymphocytic leukaemia (n = 1), sepsis (n = 1) and unknown cause (n = 1). 
fEight TDF-treated patients died, due to malignancy (n = 2), cardiac failure and multiple organ dysfunction (n = 1), cardiogenic shock (n = 1), cerebral 
haemorrhage (n = 1), sepsis (n = 1) and unknown cause (n = 2). Four ETV-treated patients died, due to pneumonia and multiple organ dysfunction 
(n = 1) and unknown cause (n = 3). 
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The retrospective design of this study confers important lim-
itations. While the data capture process was designed to minimise 
potential bias, the high proportion of missing data limits the anal-
ysis and there was potential for measurement error. In addition, 
data capture wording may have been misinterpreted, which was of 
particular concern for determining the relationship between the oc-
currence of renal impairment and drug initiation, leading to a lack 
of exact renal laboratory data at baseline for 77 patients (all with 
pre-existing renal impairment: 37 TDF; 40 ETV). However, findings 
did not differ between the multiple imputation approach used and 
complete case analyses (data not shown), indicating that overall con-
clusions were unaffected. Differences in the number of visits and 
follow-up investigations between patients may introduce impreci-
sion, while subgroup analyses risk type I or II errors since the study 
was statistically powered based on the primary objective. There is 
the potential for imbalances in baseline characteristics; for example, 
ETV may have been preferentially selected for use in older patients 
with comorbidities, although we used propensity score weighting to 
balance comorbidities as much as possible. However, this real-world, 
multicentre study analysed a large group of CHB patients with either 
pre-existing renal impairment or renal impairment after treatment 
initiation, including patients with cirrhosis and relevant comorbidi-
ties. Thus, it provides valuable insights into the safety and effective-
ness of TDF and ETV in two different contexts of renal impairment 
important for clinical practice.
In conclusion, in this large multinational, real-world study, the 
overall safety profile was similar between TDF and ETV for CHB 
patients who experienced either moderate or severe pre-existing 











Rate per 1000 
person-years (95% 
CI)b 




Renal impairment before treatment initiation
Patients experiencing any 
AE of special interest
ETV 9 8 (8.8) 318.2 25.1 (10.9-49.5) Reference —
TDF 21 20 (18.7) 384.5 52.0 (31.8-80.3) 2.05 (0.89-4.75) 0.094
Presence of a renal tubular 
dysfunction AE
ETV 0 0 — — — —
TDFd  7 (33.3) 7 (6.5) 413.1 16.9 (6.8-34.9) NE —
Renal AEs leading to drug 
discontinuation
ETV 0 0 — — — —
TDF 9 (42.9) 9 (8.4) 413.3 21.8 (10.0-41.3) NE —
Renal SAEs including those 
leading to deathe 
ETV 2 (22.2) 2 (2.2) 329.7 6.1 (0.7-21.9) Reference —
TDF 4 (19.0) 4 (3.7) 410.9 9.7 (2.7-24.9) 1.12 (0.23-5.52) 0.887
Decline in renal function 
reported as AE
ETV 7 (77.8) 7 (7.7) 323.6 21.6 (8.7-44.6) Reference —
TDF 8 (38.1) 8 (7.5) 397.1 20.1 (8.7-39.7) 1.19 (0.42-3.34) 0.745
Renal impairment after treatment initiation
Patients experiencing any 
AE of special interest
ETV 3 3 (3.9) 370.4 8.1 (1.7-23.7) Reference —
TDF 27 21 (9.9) 1019.1 20.6 (12.8-31.5) 2.30 (0.27-19.84) 0.447
Presence of a renal tubular 
dysfunction AE
ETV 0 0 — — — —
TDFf  4 (14.8) 4 (1.9) 1025.6 3.9 (1.1-10.0) NE —
Renal AEs leading to drug 
discontinuation
ETV 0 0 — — — —
TDFg  17 (63.0) 15 (7.1) 1024.9 14.6 (8.2-24.1) NE —
Renal SAEs including those 
leading to deathe 
ETV 1 (33.3) 1 (1.3) 373.9 2.7 (0.1-14.9) Reference —
TDFh  9 (33.3) 5 (2.4) 1025.3 4.9 (1.6-11.4) 1.61 (0.03-81.81) 0.812
Decline in renal function 
reported as AE
ETV 2 (66.7) 2 (2.6) 373.1 5.4 (0.6-19.4) Reference —
TDF 9 (33.3) 9 (4.2) 1026.8 8.8 (4.0-16.6) 1.35 (0.09-19.31) 0.824
Abbreviations: AE, adverse event; AESI, adverse event of special interest; CI, confidence interval; ETV, entecavir; NE, not estimable; SAE, serious 
adverse event; TDF, tenofovir disoproxil fumarate.
aNo patients experienced renal AEs leading to initiation of dialysis. 
bBased on time to first experienced AE of special interest. 
cIncidence rate ratio was calculated using multiple imputation and an inverse probability treatment weighted approach. 
dThe reported Preferred Terms were renal tubular disorder (n = 6) and Fanconi syndrome acquired (n = 1). 
eNo renal SAEs leading to death were reported. 
fThe reported Preferred Terms were renal tubular disorder (n = 3) and renal tubular necrosis (n = 1). 
gOne patient experienced three AEs of this category. 
hTwo patients experienced the same type of SAE multiple times (two and four times respectively). 
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renal impairment or renal impairment beginning after treatment 
initiation. However, higher proportions of AEs of special inter-
est, including renal tubular dysfunction, were observed in TDF- 
vs ETV-treated patients in both renal impairment subgroups. 
Effectiveness was similar between TDF and ETV for both renal 
impairment subgroups. Our findings support the current prescrib-
ing information and renal function assessment recommendations 
for both therapies.
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